Alterity Therapeutics Ltd Share Price Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 6.06Cr 5.41Cr 5.05Cr 4.59Cr 8.64Cr 586.18Cr 8.71Cr 61Cr 24Cr 298.11Cr 23Cr 22Cr 958.35Cr | P/E 2027 * |
-3.71x | P/E 2028 * | -0.35x |
|---|---|---|---|---|---|
| Enterprise Value | 5.06Cr 4.52Cr 4.22Cr 3.83Cr 7.22Cr 489.9Cr 7.28Cr 51Cr 20Cr 249.15Cr 19Cr 19Cr 800.94Cr | EV / Sales 2027 * |
46.7x | EV / Sales 2028 * | 12.1x |
| Free-Float |
97.02% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
| Director of Finance/CFO | - | 30/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 6.06Cr | |
| +4.16% | +4.16% | +49.37% | +94.17% | 7.47TCr | |
| -16.17% | -16.53% | +2.23% | +50.43% | 5.87TCr | |
| -2.08% | +1.07% | +4.00% | +32.07% | 4.84TCr | |
| +0.50% | -2.14% | +331.33% | +702.20% | 4.31TCr | |
| -0.72% | -3.99% | +28.50% | +29.94% | 4.25TCr | |
| +0.34% | -0.52% | +6.56% | +109.35% | 4.14TCr | |
| -0.11% | +1.96% | +9.19% | +52.66% | 3.13TCr | |
| -0.50% | -3.10% | -10.19% | -14.35% | 2.39TCr | |
| -3.32% | -10.86% | -37.32% | +316.28% | 2.22TCr | |
| Average | -1.59% | -2.18% | +42.63% | +152.53% | 4.29TCr | |
| Weighted average by Cap. | -2.14% | -1.56% | +49.14% | +144.80% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 10.84L 10L 9L 8L 15.45L 10Cr 15.57L 1.09Cr 42.41L 5.33Cr 40.68L 39.8L 17Cr | 19.54L 17.46L 16.29L 14.79L 27.86L 19Cr 28.07L 1.96Cr 76.46L 9.61Cr 73.34L 71.76L 31Cr |
| Net income | -2.73Cr -2.44Cr -2.28Cr -2.07Cr -3.89Cr -264.2Cr -3.92Cr -27Cr -11Cr -134.37Cr -10Cr -10Cr -431.95Cr | -3.07Cr -2.74Cr -2.56Cr -2.32Cr -4.38Cr -296.92Cr -4.41Cr -31Cr -12Cr -151Cr -12Cr -11Cr -485.43Cr |
| Net Debt | -99.53L -88.93L -82.97L -75.36L -1.42Cr -96Cr -1.43Cr -9.97Cr -3.9Cr -49Cr -3.74Cr -3.66Cr -157.41Cr | -3.69Cr -3.3Cr -3.08Cr -2.8Cr -5.27Cr -357.27Cr -5.31Cr -37Cr -14Cr -181.7Cr -14Cr -14Cr -584.11Cr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
